Morin (C5297): Natural Flavonoid Antioxidant and Mitochondrial Energy Metabolism Modulator

Executive Summary: Morin (2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one) is a well-characterized natural flavonoid compound with established antioxidant, anti-inflammatory, and mitochondrial modulating properties (Yang et al., 2025). It inhibits adenosine 5′-monophosphate deaminase (AMPD), leading to improved mitochondrial energy metabolism and cellular protection (DOI). Morin displays high purity (≥96.81%) and validated solubility profiles, making it suitable for research applications in diabetes, cancer, and neurodegeneration (APExBIO). Its fluorescent chelating properties allow its use as an aluminum ion probe, broadening utility in biochemical assays. Rigorous peer-reviewed data support Morin’s mechanism of action and efficacy in cellular and animal models.

Biological Rationale

Morin is a flavonoid isolated from Maclura pomifera, structurally defined as 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one, with a molecular weight of 302.24 Daltons (APExBIO). Flavonoids, including Morin, are recognized for their antioxidant capacity and ability to modulate redox-sensitive signaling pathways. Mitochondrial dysfunction and oxidative stress are implicated in the pathogenesis of metabolic, renal, and neurodegenerative diseases. Podocyte injury, driven by mitochondrial energy disturbance, contributes to the progression of kidney disease and is exacerbated by high-fructose diets (Yang et al., 2025). Maintaining mitochondrial energy homeostasis in these cells is therefore a central aim of translational research targeting metabolic disease.

Mechanism of Action of Morin

Morin exerts its primary bioactivity by inhibiting adenosine 5′-monophosphate deaminase (AMPD), a key enzyme in the purine nucleotide cycle (PNC). Inhibition of AMPD prevents excessive AMP deamination, preserving mitochondrial energy metabolism and ATP levels under metabolic stress (Yang et al., 2025). Molecular docking studies confirm Morin’s strong binding affinity for AMPD2 isoform, and siRNA knockdown experiments corroborate the centrality of AMPD2 in mediating Morin’s effects. Additionally, Morin’s polyhydroxylated structure confers potent antioxidant and metal-chelating properties, enabling its use as a fluorescent probe for aluminum ions in analytical biochemistry (Related Article). The compound is insoluble in water but dissolves in DMSO (≥19.53 mg/mL) and ethanol (≥6.04 mg/mL), supporting its compatibility with diverse experimental workflows (APExBIO).

Evidence & Benchmarks

• Morin (10–50 µM, DMSO solution) significantly inhibits fructose-induced upregulation of AMPD activity in mouse podocyte clone-5 cells, preserving mitochondrial membrane potential and ATP production (Yang et al., 2025).
• In high-fructose diet rat models, Morin administration (50 mg/kg/day, oral gavage, 4 weeks) reduces podocyte foot process effacement and urinary albumin-to-creatinine ratio, indicating improved renal function (DOI).
• Morin demonstrates strong in silico binding to AMPD2, with docking energies consistent with direct enzymatic inhibition (Table 1, Yang et al., 2025).
• Morin’s high purity (≥96.81%) is validated by HPLC, MS, and NMR, ensuring batch-to-batch reproducibility (APExBIO).
• Morin chelates Al³⁺ ions, exhibiting strong fluorescence suitable for sensitive metal ion detection in biochemical assays (Article).

This article extends the scope of Morin (C5297): Scenario-Driven Solutions for Cell Viability by integrating new peer-reviewed mechanistic evidence and providing precise solubility and purity data. It also clarifies distinctions from Morin: Natural Flavonoid Antioxidant for Mitochondrial Modulation by detailing Morin’s enzyme target profile and workflow integration parameters.

Applications, Limits & Misconceptions

Morin’s validated applications include:

• Protecting podocytes from fructose-induced mitochondrial dysfunction in kidney disease models (Yang et al., 2025).
• Modulating energy metabolism in diabetes, cancer, and neurodegeneration research (Benchmarks Article).
• Serving as a fluorescent probe for Al³⁺ detection in bioanalytical workflows (Related Article).

Common Pitfalls or Misconceptions

• Morin is not effective as a therapeutic agent in clinical settings; all claims are currently restricted to preclinical models and in vitro/in vivo research.
• Morin is insoluble in water; improper solvent use may lead to precipitation and unreliable dosing (APExBIO).
• Its fluorescent probe activity is specific to Al³⁺ and may not generalize to all metal ions.
• Long-term solution stability is not guaranteed; Morin solutions should be freshly prepared and stored at -20°C for short-term use only.
• Not all observed effects are independent of the solvent system; DMSO or ethanol must be controlled in experimental design.

Workflow Integration & Parameters

Morin (C5297, supplied by APExBIO) is delivered as a high-purity powder suitable for research use. It is insoluble in water but dissolves in DMSO (≥19.53 mg/mL) and ethanol (≥6.04 mg/mL); solubilization should occur under inert atmosphere if possible. Typical working concentrations range from 5–100 µM in cell culture and up to 50 mg/kg/day in rodent studies (Yang et al., 2025). Solutions should be freshly prepared, protected from light, and stored at -20°C for a maximum of several days. Analytical verification by HPLC or MS is recommended for critical experiments. For fluorescence-based detection of Al³⁺, excitation/emission parameters should be optimized for Morin’s chelation complex (Related Article).

Conclusion & Outlook

Morin is a versatile, high-purity natural flavonoid antioxidant with well-validated mechanisms in mitochondrial energy metabolism modulation and AMPD inhibition (Yang et al., 2025). Its applications span diabetes, renal, and neurodegenerative disease model research, and its fluorescent chelating properties further expand its utility in analytical workflows. The C5297 kit from APExBIO provides a rigorously characterized and reproducible source for advanced biomedical investigations. Ongoing research will clarify clinical translatability and further refine workflow-specific parameters. For more on Morin’s integration into translational metabolic research, see Morin as a Translational Catalyst: Mechanistic Insights, which this article updates by providing direct mechanistic evidence and product-specific guidance.